CN212213944U - Hollow-out type artificial lens medicine carrying system - Google Patents
Hollow-out type artificial lens medicine carrying system Download PDFInfo
- Publication number
- CN212213944U CN212213944U CN202020448772.2U CN202020448772U CN212213944U CN 212213944 U CN212213944 U CN 212213944U CN 202020448772 U CN202020448772 U CN 202020448772U CN 212213944 U CN212213944 U CN 212213944U
- Authority
- CN
- China
- Prior art keywords
- intraocular lens
- lens
- hollow
- medicine
- artificial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Prostheses (AREA)
Abstract
The utility model relates to the technical field of medical treatment, concretely relates to fretwork formula intraocular lens medicine carrying system. The utility model provides a hollow-out intraocular lens drug-loading system, which comprises an intraocular lens optical part and two intraocular lens loops which are connected with the upper end and the lower end of the intraocular lens optical part and are in a C shape; the interiors of the two artificial lens loops are of hollow structures; the artificial lens loop is made of materials capable of slowly releasing medicines. The utility model is a design which can package and carry the medicine, lead the medicine to be slowly and accurately released and does not influence the self function of the crystalline lens.
Description
Technical Field
The utility model relates to the technical field of medical treatment, concretely relates to fretwork formula intraocular lens medicine carrying system.
Background
At present, most of the drugs commonly used in scientific research for inhibiting after cataract are proved to be capable of obviously inhibiting the growth of LEC in a laboratory or weakening the process of EMT, and the drug therapy has broad prospects in the future, but most of the drugs belong to the animal test stage at present, the most important reason is that most of antimetabolites have the defects of poor water solubility, large toxic and side effects, high drug release speed and the like, which seriously hinders the progress of scientific research, and in the face of the challenge, the most important solution is to develop a new device which can target on lens epithelial cells and has lasting action time, the sealing bag lavage technology and the nano slow release technology are proposed in a period of time, but are not widely put into use at present, some scientists think of making articles on the implanted intraocular lens, but how to utilize the intraocular lens to fix the level, The characteristics of long action time and the like are always puzzling the problems, and the medicine embedding is proposed on the optical part of the crystalline lens, but the defects of possible change of optical imaging and the like exist. Therefore, the invention is a design which can package the medicine, lead the medicine to be slowly and accurately released and does not influence the self function of the crystalline lens, and is very important.
SUMMERY OF THE UTILITY MODEL
In order to solve the problems, the utility model provides a hollow-out intraocular lens drug-loading system, which comprises an intraocular lens optical part and C-shaped intraocular lens loops which are symmetrically arranged and connected with the two sides of the intraocular lens optical part; an accommodating cavity for accommodating the medicine is arranged in each artificial lens loop; wherein, the artificial lens loop is prepared by materials capable of slowly releasing medicines.
Preferably, the receiving cavity inside the intraocular lens haptic is a hollow conduit extending lengthwise of the intraocular lens haptic; the number of the accommodating cavities is one or more.
The utility model has the advantages that:
the utility model is applied to the combined artificial lens implantation of cataract ultrasonic emulsification extirpation or mainly applied to trauma, congenital ciliary zonule relaxation or fracture, lens dislocation and other cases. Specifically, two intraocular lens loops of the intraocular lens are composed of hollow pipelines, drugs are injected into the pipelines by special means, and the pipeline walls are composed of special slow release devices, so that the drugs can slowly seep out, and the aims of accurately releasing the drugs in the appointed position (a capsular bag), improving the drug concentration of an action target and reducing the damage to surrounding tissues are fulfilled.
The 'hollowed-out' artificial lens cannot damage the structure of the optical area of the crystalline lens and cannot cause any refractive influence on a patient; the hollow-out type artificial crystal can be internally provided with a large amount of slow-release medicines, and the property of the tube wall (carrier) can be changed according to the medicines loaded inside, so that the loading of various medicines is convenient; the 'hollowed-out' artificial lens does not change the maximum diameter of the artificial lens and does not need to enlarge an operation incision manually.
Drawings
The present invention is further explained by using the drawings, but the embodiments in the drawings do not constitute any limitation to the present invention, and for those skilled in the art, other drawings can be obtained according to the following drawings without any inventive work.
FIG. 1 is a schematic diagram of the front side of a hollow intraocular lens drug delivery system of the present invention;
FIG. 2 is a schematic side view of a hollow intraocular lens drug delivery system of the present invention;
fig. 3 is a schematic view of the intraocular lens haptics of the present invention.
FIG. 4 is a schematic view of the channel structure of the intraocular lens loop of the present invention.
Reference numerals: an artificial lens optical part 1, an artificial lens loop 2 and a containing cavity 3.
Detailed Description
Posterior Cataract (PCO) is a common complication after "phacoemulsification combined with intraocular lens implantation". According to statistics, the incidence rate of cataract after cataract operation of adults is 12-67%, and even 100% of cataract after cataract operation of children. The pathogenesis of PCO is related to residual lens epithelial cells after cataract surgery, which produce microfibrils through proliferation, migration, epithelial-mesenchymal transition (EMT), forming a secondary cataract. For the clinical after cataract patients, a Nd-YAG laser incision treatment method for capsular sac after clouding in the pupillary region is mostly adopted at present, and the report shows that the visual function of the after cataract patients without visual impairment can be obviously improved even if the Nd-YAG laser incision treatment method is carried out on the after cataract patients. However, there are continuous reports of research: after the laser treatment, various related diseases are easy to be complicated, such as artificial lens displacement and refractive state change, artificial lens damage, iritis or uveitis, cystoid macular edema, anterior hemorrhage, macular rupture and other complications. Intraocular drug therapy for posterior capsule disorders has been a hot spot of recent research, and the mechanism of drug therapy is mainly divided into the following two types aiming at the pathogenesis of the posterior capsule disorders: one is to promote Lens Epithelial Cell (LEC) apoptosis; another is to inhibit the migration, transformation, especially epithelial-to-mesenchymal transition (EMT), of LECs. At present, the drugs commonly used in scientific research for inhibiting after cataract are mainly classified into the following categories according to their action mechanisms: an antimetabolite: representative drugs are: paclitaxel, 5-fluorouracil, methotrexate, etc. Anti-inflammatory drugs: glucocorticoids, diclofenac sodium and the like. And thirdly, other: representative of the substances: gefitinib, somatostatin, curcumin and the like.
The method for solving the complications is to develop a new device which can target on lens epithelial cells and has lasting action time, a sealing bag lavage technology and a nano slow release technology are proposed for a while, but are not widely used at present, some scientists think of making articles on the implanted intraocular lens, but how to utilize the characteristics of positioning, long action time and the like of the intraocular lens is a problem which always troubles people, and some scientists propose to embed medicines in an optical part of the lens, but have the defects of possibly causing the change of optical imaging and the like. The utility model develops a design which can package and carry the medicine to make the medicine release slowly and accurately and does not influence the function of the crystalline lens.
The invention will be further described with reference to the following examples.
Examples
1. The structure and characteristics of the utility model
Referring to fig. 1-4, a hollow intraocular lens drug delivery system comprises an intraocular lens optical part 1 and C-shaped intraocular lens haptics 2 connected to two sides of the intraocular lens optical part 1 and symmetrically arranged; an accommodating cavity 3 for accommodating medicines is arranged in each artificial lens loop 2; wherein, the artificial lens loop 2 is made of materials capable of slowly releasing medicines.
The accommodating cavity 3 inside the artificial lens loop 2 is a hollow pipeline extending along the length direction of the artificial lens loop 2; the number of the accommodating cavities 3 is one or more.
The utility model is applied to the combined artificial lens implantation of cataract ultrasonic emulsification extirpation or mainly applied to trauma, congenital ciliary zonule relaxation or fracture, lens dislocation and other cases. Specifically, the two intraocular lens loops 22 of the intraocular lens are composed of hollow pipelines, the medicine 3 is injected into the pipelines by special means, and the pipeline wall is a special slow release device, so that the medicine 3 can slowly seep out, thereby achieving the purposes of accurately releasing the medicine 3 at a specified position (in a capsular bag), improving the concentration of the medicine 3 at an action target and reducing the damage to surrounding tissues.
The 'hollowed-out' artificial lens cannot damage the structure of the optical area of the crystalline lens and cannot cause any refractive influence on a patient; the hollow-out type artificial crystal can be internally provided with a large amount of slow-release medicines, and the property of the tube wall (carrier) can be changed according to the medicines loaded inside, so that the loading of various medicines is convenient; the 'hollowed-out' artificial lens does not change the maximum diameter of the artificial lens and does not need to enlarge an operation incision manually.
2. Detailed description of the preferred embodiment
Taking the right eye operation of the patient as an example:
before operation, the compound tropicamide is dripped three times for mydriasis and once in 30 min. Three times of surface anesthesia are carried out on proparacaine hydrochloride eye drops 10min before the operation.
The patient's right eye is disinfected regularly and covered with eye speculum after the surface is anesthetized satisfactorily, the right eye is wiped twice with conjunctival sac povidone-iodine cotton ball, and the eye speculum is washed with normal saline, re-dripped with surface anesthetic and added with cornea protectant.
And adjusting and fixing the position of the microscope. The ultrasonic emulsifying machine and the injection and suction pipeline are connected, and the operation is started after the test is carried out without errors.
A2 mm wide incision of the transparent limbus was made at 2 points with a 3.2mm triangular knife and a 3mm wide incision of the transparent limbus was made at 11 points, and the viscoelastic was injected into the anterior chamber with a 5ml syringe. The diameter of the continuous annular capsulorhexis is about 5.5mm by using capsulorhexis forceps. The 5ml syringe was used to fully separate the crystals by incision. The phacoemulsification head extends into the central portion of the anterior chamber etched nucleus, phacoemulsification and aspirates out the crystal nucleus (class IV, V crystal nuclei are cleaved using a nucleus cleaving knife). The phacoemulsification machine is adjusted to I/A gear to suck out residual cortex. A5 ml syringe injected a small amount of viscoelastic into the anterior chamber.
After checking the model and the degree of the intraocular lens with an assistant, firstly injecting the medicine 3 into the hollow intraocular lens loop 22 by a special means, then installing the intraocular lens into a booster, implanting the intraocular lens with a slow release system into the capsular bag, and adjusting the position of the intraocular lens by a small hook.
The viscoelastic agent in the anterior chamber was replaced again with I/A, and the eyelid retractor was removed after the watertightness was checked. The eyes were cleaned with saline, covered with tobramycin dexamethasone eye ointment and bandaged with eye mask. The operation is finished.
It should be finally noted that the above embodiments are only intended to illustrate the technical solutions of the present invention, and not to limit the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solutions of the present invention can be modified or replaced with equivalents without departing from the spirit and scope of the technical solutions of the present invention.
Claims (2)
1. A hollow-out intraocular lens drug-loading system is characterized by comprising an intraocular lens optical part and C-shaped intraocular lens loops which are symmetrically connected to two sides of the intraocular lens optical part; an accommodating cavity for accommodating the medicine is arranged in each artificial lens loop; wherein, the artificial lens loop is prepared by materials capable of slowly releasing medicines.
2. The system of claim 1 wherein the receiving chamber within the intraocular lens haptics is a hollow channel extending lengthwise along the intraocular lens haptics; the number of the accommodating cavities is one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020448772.2U CN212213944U (en) | 2020-03-31 | 2020-03-31 | Hollow-out type artificial lens medicine carrying system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020448772.2U CN212213944U (en) | 2020-03-31 | 2020-03-31 | Hollow-out type artificial lens medicine carrying system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN212213944U true CN212213944U (en) | 2020-12-25 |
Family
ID=73905795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202020448772.2U Expired - Fee Related CN212213944U (en) | 2020-03-31 | 2020-03-31 | Hollow-out type artificial lens medicine carrying system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN212213944U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998906A (en) * | 2021-01-25 | 2021-06-22 | 广州睿康医疗科技有限公司 | Multilayer composite structure drug-loaded airway stent and preparation method thereof |
| CN117425450A (en) * | 2021-06-03 | 2024-01-19 | 杰利西眼科股份有限公司 | Intraocular lens with anamorphic optics and stabilization |
-
2020
- 2020-03-31 CN CN202020448772.2U patent/CN212213944U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998906A (en) * | 2021-01-25 | 2021-06-22 | 广州睿康医疗科技有限公司 | Multilayer composite structure drug-loaded airway stent and preparation method thereof |
| CN117425450A (en) * | 2021-06-03 | 2024-01-19 | 杰利西眼科股份有限公司 | Intraocular lens with anamorphic optics and stabilization |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8734463B2 (en) | Method of implanting an intraocular lens | |
| US6533769B2 (en) | Method for use in cataract surgery | |
| CA2230947C (en) | Implantable controlled release device to deliver drugs directly to an internal portion of the body | |
| US20050251254A1 (en) | Method of implanting accommodating intraocular lenses | |
| US6413262B2 (en) | Method of crystalline lens replacement | |
| Kosrirukvongs et al. | Corneal endothelial changes after divide and conquer versus chip and flip phacoemulsification | |
| US11517422B2 (en) | Intraocular implants comprising drug-eluting materials with time release characteristics | |
| CN212213944U (en) | Hollow-out type artificial lens medicine carrying system | |
| WO2007018621A1 (en) | Drug delivery system and method | |
| EA032183B1 (en) | Intraocular drug delivery device, process for preparing same and methods of using same | |
| JPH07116030B2 (en) | Residual lens substance removal aid | |
| Basti et al. | Prospective evaluation of corneal endothelial cell loss after pediatric cataract surgery | |
| CN203220483U (en) | Artificial-crystal drug releasing apparatus capable of opening by laser | |
| CN212213939U (en) | Corner embedded artificial lens medicine carrying system | |
| Kim et al. | Effect of haptic material and number of intraocular lens on anterior capsule contraction after cataract surgery | |
| CN212213940U (en) | Embedded artificial lens medicine carrying system | |
| WO2024011448A1 (en) | High-adhesion artificial corneal endothelia graft, and preparation method therefor and use thereof | |
| CN212213942U (en) | Wearable artificial lens medicine carrying system | |
| Matsuo et al. | Curved-tip disposable injector (OUReP Injector) to insert photoelectric dye-coupled polyethylene film (OUReP) as retinal prosthesis into subretinal space of rabbit eyes | |
| Dahlmann et al. | Acrylic lens exchange for late opacification of the optic | |
| RU2362524C1 (en) | Cataract extraction, vitrectomy and intraocular lens implantation technique | |
| Peiffer Jr et al. | Experimental evaluation of a phakic anterior chamber implant in a primate model Part I. Clinical observations | |
| Santosh et al. | Studies on influence of capsular tension ring (CTR) on intraocular lens (IOL) implantation following phacoemulsification in cataractous dogs | |
| SU1713581A1 (en) | Method for cataract extraction | |
| CN108721315A (en) | Applications of the small molecule nucleic acid miR-21 in treating glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201225 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |